Recently, the company announced its entry into the obesity and metabolic health segment with the launch of Poviztra, a semaglutide injection for chronic weight management. Shares of Emcure Pharmaceuticals Ltd ended higher on Tuesday, December 23, by 3.40% at ₹1,426 on the NSE.Recently, the company announced its entry into the obesity and metabolic health segment with the launch of Poviztra, a semaglutide injection for chronic weight management. Shares of Emcure Pharmaceuticals Ltd ended higher on Tuesday, December 23, by 3.40% at ₹1,426 on the NSE.
Emcure Pharma's Gujarat plant gets all-clear from FDA
API Publisher